DGD. A. Golovkina

D. A. Golovkina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


D. A. Golovkina has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Safety and tolerability of Aviandr (maritupirdine) in long-term therapy of generalized anxiety disorder: results of a 36-week post-marketing observational study

    by M. A. Kinkulkina, B. A. Volel, E. A. Smolyarchuk, E. N. Morozov, A. V. Ivaschenko, I. A. Ivaschenko, N. N. Ivanets, T. I. Avdeeva, Yu. G. Tikhonova, T. A. Izyumina, et al.

    Long-term therapy is necessary for the prevention of relapses of generalized anxiety disorder (GAD), and adherence to it may be hindered by the development of adverse events (AEs). The new domestic drug Aviandr (maritupirdine) has shown efficacy and good tolerability in the treatment of GAD in clinical trials. Objective: to evaluate the safety and tolerability profile of long-term (36-week) GAD therapy with Aviandr (maritupirdine) in real-world clinical practice. Material and methods. An open-label, non-comparative prospective study included 126 patients over 18 years of age with an established diagnosis of GAD. The frequency and severity of AEs, the dynamics of daytime sleepiness on a visual analogue scale (VAS), the presence of with-drawal syndrome, and tolerability features in special patient groups (elderly individuals, patients with somatic comorbidity) were assessed. Results. The vast majority of patients (98.4%) completed the 36-week course of therapy; no patient discontinued the drug due to AEs. Drug-related AEs were registered in 13.49% of patients, predominantly mild in severity (73.1%). The most common AE was somnolence (5.56%), but no clinically significant sedation was noted: the VAS daytime sleepiness score decreased significantly from 39.72±26.29 to 17.73±17.23 by week 36 (pConclusion. Aviandr demonstrates a high safety and tolerability profile in long-term GAD therapy. The absence of sedation, worsening of anxiety, sexual dysfunction, and withdrawal syndrome ensures high adherence to treatment and makes the drug a safe agent of choice for elderly patients and individuals with concomitant somatic pathology.

  • Open Access

    A differentiated approach to the diagnosis and treatment of mental disorders in a patient with Ehlers-Danlos syndrome (clinical observation)

    by N. A. Tyuvina, T. N. Maksimova, D. A. Golovkina, T. V. Segal, F. A. Litvin

    Somatic and neurological hereditary disorders, which arise as a result of various genetic mutations and usually manifest from childhood, are often accompanied by various mental health disorders. These may include mental disorders of exogenous-organic origin, personality disorders that are exacerbated or develop against a background of prolonged, severe, disabling illness with reactions of decompensation and maladjustment; endogenous disorders may also occur comorbidity. Mental disorders in themselves complicate the clinical picture, reduce quality of life and exacerbate social maladjustment. Furthermore, mental disorders, particularly those of an anxiety-depressive nature, can aggravate somatic pathology via a psychosomatic mechanism, a factor that must be taken into account when providing care for such patients. To illustrate the above, we present a clinical case of a patient with Ehlers–Danlos syndrome (a hereditary connective tissue dysplasia), which manifests, in addition to musculoskeletal pathology, as pronounced cardiovascular, neurological and mental disorders. The latter are represented by an organic personality disorder of a predominantly hysterical nature with anxiety-depressive maladaptive reactions. The difficulties of differential diagnosis of personality disorders and therapeutic aspects are discussed.

  • Efficacy and safety of AVIANDR in the treatment of panic disorder: results of the first stage of the multicenter, randomized, placebo-controlled study

    by M.A. Kinkulkina, B.A. Volel, E.A. Smolyarchuk, E.N. Morozov, A.V. Ivaschenko, A.A. Ivaschenko, N.N. Ivanets, V.G. Zilov, Yu.G. Tikhonova, T.A. Izyumina, et al.

    Objective. To evaluate the efficacy and safety of non-benzodiazepine anxiolytic maritupirdine (Aviandr) in patients with panic disorder. Material and methods. In a multicenter, randomized, double-blind, placebo-controlled study with an open-label comparison, 288 patients with moderate PD were assigned to receive Aviandr 40 mg/day (n=144), placebo (n=72), or paroxetine 40 mg/day (n=72). The treatment duration was 12 weeks. Clinical and psychopathological, psychometric methods and statistical analysis were used. The Panic Disorder Severity Scale (PDSS), the Structured Interview Guide for the Hamilton Anxiety Scale (SIGH-A), the Clinical Global Impression Scale (CGI), the Visual Analog Scale (VAS) of daytime sleepiness and the Sheehan Disability Scale (SDS) were used for a standardized assessment of the state change. The primary endpoint was the change in Panic Disorder Severity Scale (PDSS) total score at week 12. Results. The PDSS score reduction in the Aviandr group (–4.99) was statistically and clinically significantly greater than in the placebo group (–2.28; p=0.047). The drug demonstrated a rapid onset of action, with significant improvement beginning at week 2. Aviandr’s efficacy on secondary endpoints (SIGH-A and CGI) was also superior to placebo. The need for symptomatic hydroxyzine therapy was significantly lower in the Aviandr group. The safety profile was favorable, with adverse event rates comparable to placebo (44.44%) and lower than in the paroxetine group (50%). No serious adverse events were recorded. Conclusion. Aviandr demonstrated statistically significant superiority over placebo, rapid onset of action, and a favorable safety profile, making it a promising treatment option for panic disorder.

  • Long-term treatment of generalised anxiety disorder with Aviandr: results of a 36-week post-registration observational study

    by M. A. Kinkulkina, B. A. Volel, E. A. Smolyarchuk, E. N. Morozov, A. V. Ivaschenko, A. A. Ivaschenko, N. N. Ivanets, V. G. Zilov, T. I. Avdeeva, Yu. G. Tikhonova, et al.

    The management of patients with generalised anxiety disorder (GAD) is a pressing issue in modern medicine. A new Russian drug, Aviandr (maritupridine), has demonstrated efficacy and good tolerability in the treatment of GAD in clinical trials. Objective : To study the effectiveness of treating GAD with Aviandr in real clinical practice. Material and methods . An open-label, non-comparative prospective study included 98 patients over the age of 18 with a confirmed diagnosis of GAD. Patients received Aviandr therapy and were monitored on an outpatient basis for 36 weeks. Clinical-psychopathological and psychometric examinations were conducted before treatment and at 2, 8, 16, 24, and 36 weeks after the start of treatment. Anxiety symptoms were measured using the Hamilton Anxiety Rating Scale (structured interview, SIGH-A). Additionally, symptoms of depression (Montgomery-Asberg Depression Rating Scale – MADRS), cognitive functions (Montreal Cognitive Assessment Scale – MoCA), and the somatic condition of patients were assessed. Results. Aviandr has proven to be an effective drug for treating GAD. A statistically significant reduction in the total SIGH-A score was observed as early as the second week of therapy (from 22.06±5.80 before therapy to 19.12±5.91; pConclusion . The use of Aviandr is an effective method of treating GAD. The therapeutic effect of the drug manifested itself gradually, demonstrating a progressive increase throughout the course of therapy, with maximum symptom reduction achieved by the 36th week of treatment.


  • Efficacy and safety of Aviandr in patients with anxiety disorders after coronavirus infection (COVID-19): interim results of a multicenter observational post-registration study

    by M. A. Kinkulkina, A. B. Danilov, B. A. Volel, E. N. Morozov, D. O. Rozhkov, San Diego USA ChemDiv Inc., A. A. Ivaschenko, Moscow ChemRar Pharma, N. N. Ivanets, Yu. G. Tikhonova, et al.

    Prevalence of anxiety disorders has increased in last decades, specifically in COVID-19 pandemic. Despite the frequency and burden of post-COVID anxiety disorders, there are still no recommendations for the treatment of these conditions. The article presents the interim results of a post-registration multicenter observational study of the efficacy and safety of a new original drug Aviandr in the treatment of anxiety developing after COVID-19. The study included 170 patients over 18 years of age treated by Aviandr for 6 weeks at a dose of 20 mg 2 times a day. All patients completed 6 weeks of treatment and 2 weeks of follow-up. The decrease in the average total score of the Hamilton Rating Scale for Anxiety (SIGH-A) was 77.13 % of the baseline values. Most patients experienced clinical improvement; 72.35 % patients have reached remission by week 6 of therapy. The drug was equally effective in different age groups (≤/> 65 years). It is important to note that Aviandr was effective in relieving both mental and somatic anxiety, measured with SIGH-A scale — the reduction in average scores was 75.13 % and 79.12 %, respectively. The study drug showed a good safety profile. Adverse events were observed in 5.88 % of patients; 85.7 % of AEs were mild, only 14.3 % were moderate. Thus, Aviandr showed good efficacy in the treatment of anxiety disorders after COVID-19. The absence of withdrawal syndrome, drug dependence, a high safety profile, including in elderly patients, make Aviandr a good choice for use in clinical practice.


  • Post-COVID cognitive impairment, level of depression and anxiety in university students

    by FSAEI HE I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), M.A. Kinkulkina, A.K. Vasyuta, D.A. Golovkina, S.A. Repin, T.F. Bogatov, Yu.G. Tikhonova, V.G. Zilov

    Recently, a significant amount of research has focused on the impact of COVID-19 on mental health. One of the increasingly common long-term consequences of COVID-19 is its effect on cognitive function, even in patients with an initially mild course of the acute illness. The article presents the results of a study of cognitive impairment and anxiety and depression levels among students of a higher medical educational institution. The study consisted of a continuous screening survey of students who had and had not experienced COVID-19 using an original questionnaire, as well as psychometric scales: Montreal Cognitive Assessment (MoCA), Patient Health Questionnaire (PHQ-9), and Generalized Anxiety Disorder-7 (GAD-7). Based on the screening results, two groups were formed (those who had COVID-19 and those who did not), and a comparative analysis was carried out. It was found that a third (32.4%) of young people who had COVID-19 developed cognitive impairment. In students who were not ill, cognitive impairment was detected half as often – 16.8%. It was revealed that regardless of the fact of having suffered an infectious disease, a quarter of students experienced increased anxiety and decreased mood. Affective experiences, in turn, negatively affected cognitive functioning and caused young people to be more attentive to their health, including mental health, which was accompanied by a large number of positive responses when using the PHQ-9 and GAD-7 screening questionnaires.